MoonLake Q3 cash $493.9M; Phase 3 HS readout on track for mid-2025

MoonLake Immunotherapeutics

Cash, equivalents and short-term debt securities of $493.9M as of Sep 30; runway to end of 2026.
R&D expenses of $35.7M in Q3, up from $23.7M prior quarter, driven by Phase 3 HS ramp-up.
Phase 3 VELA program in HS actively enrolling; primary endpoint readout anticipated as of mid-2025.
Phase 3 PsA program (IZAR-1 and IZAR-2) enrollment expected to commence imminently.
Additional Phase 2 trials in PPP, axSpA, and Phase 3 adolescent HS to start around year-end 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.